Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2016

View Archived Issues

Prothena reports phase Ib results for PRX-002 in Parkinson's disease

FDA removes partial clinical hold on NY-ESO SPEAR study

Retrophin reaches SPA agreement with FDA for phase III trial of RE-024 for PKAN

Galectin Therapeutics looking for potential strategic partnership for GR-MD-02

Selecta Biosciences gets worldwide rights to candidates generated through Sanofi collaboration

FDA approves Opdivo for head and neck cancer

Blisibimod CHABLIS-SC1 phase III study does not achieve primary endpoint

FDA approves Vemlidy to treat chronic HBV infection

Assembly Biosciences starts phase Ia/Ib trial of ABI-H0731

FDA grants BTD to Seattle Genetics' brentuximab vedotin

Omeros reports nonhuman primate data for MASP-3 inhibitor OMS-906

NAALADL2 identified as a drug target for prostate cancer

Celsion reports positive data for OVATION phase Ib trial

Capricor expands CAP-1002 clinical development program in DMD

RedHill Biopharma concludes type B meeting with FDA for RBH-105 phase III program

TaiMed Biologics notifies Theratechnologies of preliminary results for phase III trial of ibalizumab

VRC-01 only slightly delays HIV rebound in clinical studies

Aptinyx wins USD 2.85 million in research grants

Bristol-Myers Squibb licenses rights to Nitto Denko's siRNA molecules

Jiangsu Hansoh Pharmaceutical patents FXR agonists

Chinese researchers report CDK/cyclin inhibitors for cancer

BGI-Shenzhen develops of calcium channel blockers

Inhibikase Therapeutics describes tyrosine kinase inhibitors

Synaptic biomarkers of cognitive decline identified in patients with dementia

Genmab to test daratumumab in combination with carfilzomib and dexamethasone in MM patients

Glucagon/thyroid hormone conjugate improves experimental metabolic conditions

Lilly's Lartruvo gets conditional approval in Europe for advanced soft tissue sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...